Related Experiment Video
Updated: Aug 19, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
[Expression of PTEN, p53 and P-glycoprotein in Non-small cell Lung Cancer and Their Predictive Values.]
Honglan Zhang1, Hong Shu, Weiguo Jiang
1Department of Pathology, Shengjing Hospital, China Medical University, Shenyang 110004, China.
Background:
Multiple drug resisting (MDR) phenotype is the sign of intrinsic or acquired resistance and is the key factor which leads to chemotherapy failure. It has been proven that PTEN, p53, P-gp expressions were related to drug resistance and prognosis of the patients with lung cancer. The aim of this study is to analyze the association of the expression of PTEN, p53, P-gp with postoperative survival in patients with non-small cell lung cancer (NSCLC), and to explore the relationship between the characteristics and drug resistance of NSCLC patients.
Methods:
A total of 61 patients with NSCLC were followed up. Immunohistochemical staining using polyclonal PTEN, p53 and P-gp antibody were performed on paraffinimbedded specimens from 61 patients with NSCLC and 20 specimens of tumor-surrounding normal lung tissue were used as control.
Results:
The PTEN expression was significantly lower in NSCLC than in tumor-surrounding normal lung tissue and the expression of p53 and P-gp were in the opposite aspects (P<0.05). Expression of PTEN was positively related with histology, clinical stage, lymphatic metastasis, p53 expression was positively related with gender, lymphatic metastasis and the three kinds of protein expression were related with prognosis (P<0.05). The expression of PTEN was related with p53 expression (r=-0.282, P<0.05), but the expression of PTEN and p53 were not related with P-gp in NSCLC (P>0.05).
Conclusions:
To some extent, the expression level of PTEN, p53 and P-gp may predict the effect of radiotherapy, chemotherapy and prognosis of NSCLC.
